Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics has expanded its distribution agreement with Henry Schein Medical to include Belgium, for their rapid point-of-care test FebriDx®, which distinguishes viral from bacterial infections in just 10 minutes. The move aims to aid healthcare professionals in making better decisions regarding antibiotic use, thus addressing the global issue of antimicrobial resistance. This partnership aligns with the company’s commitment to providing accessible quality care and managing infectious diseases effectively.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
